30 closest matches · ranked by relevance
HIV-1 Infection
Primary: GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48 — 32.7 percentage of participants
HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
Primary: Percentatge of Doravirine Dialysis Extraction Ratio (ER) — 34.3 percentage of doravirine dialysis ER
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Hepatitis C
Primary: Sustained Virologic Response (SVR12) Rate — 38 Participants
Hepatitis C · Hemodialysis · Nosocomial Infection
Primary: SVR - Sustained Virologic Response — 3; 0; 1; 0 Participants
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Hepatitis B Virus Infection
Primary: The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7 — 49; 64 Participants
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1) — 72.9; -5.2 mL/min
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
HIV Infections · AIDS
Primary: Performance of Glomerular Filtration Rate (GFR) Estimating Equations — 10.9; 5.4; 4.3; 6.4 mL/min per 1.73 m^2
Hepatitis Viruses
Primary: Number of Participants With Sustained Virologic Response (SVR12) — 46 Participants
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
HIV · Hepatitis C · Cirrhosis
Primary: Number of Participants With Sustained Virologic Response (SVR) — 38; 25 Participants
Chronic Hepatitis C · Hepatitis C Virus · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment — 94.1 percentage of participants
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
HIV Infections
Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133
End-stage Renal Disease · SARS-CoV-2 Acute Respiratory Disease · Dialysis; Complications
Primary: Number and Percentage of Total SARS-CoV-2 Tests Accepted Out of Total Tests Offered — 509; 475 Tests — p=0.90
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
Risk Behavior · Medication Adherence · HIV
Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants
End Stage Renal Disease · Thrombosis
Primary: The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability) — 0; 0…
HIV
Primary: Number of Grade 2 or Higher Related Adverse Events — 11 Events
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks Following Treatment Completion — 55.6 Percentage of participants
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Human Immunodeficiency Virus (HIV)
Primary: Number of Participants With Confirmed Virologic Response (CVR) at Week 48 — 40 Participants
End-stage Renal Disease (ESRD)
Primary: Number of Participants With Major Bleeding (MB) and Clinically Relevant Non-Major Bleeding (CRNMB) — 3; 2; 3; 3 Participants
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.3; 100.0; 84.2 percentage of participants